false
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Catalog
Hypophosphatemic Rickets
Presentation: Hypophosphatemic Rickets
Presentation: Hypophosphatemic Rickets
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this video, Dr. Lakshmi Menon, an endocrinologist, discusses the topic of hypophosphatemic rickets. She covers the role of fibroblast growth factor 23 (FGF23) in phosphate metabolism, the different forms of inherited and acquired FGF23-mediated hypophosphatemic rickets, and the treatment options for hypophosphatemic rickets. Dr. Menon explains that FGF23 reduces the tubular reabsorption of phosphate and decreases the expression of renal 1-alpha-hydroxylase, leading to hypophosphatemia. In the case of X-linked hypophosphatemia (XLH), the most common form of hereditary hypophosphatemic rickets, she discusses the clinical manifestations and treatment options, including conventional treatment with calcitriol and phosphate salt, as well as the new treatment option, burosumab. She also addresses the treatment of autosomal dominant hypophosphatemic rickets, hypophosphatemia due to IV iron infusion, tumor-induced osteomalacia, and fibrous dysplasia. Dr. Menon emphasizes the need for further research to gain a better understanding of phosphate metabolism and to improve the diagnosis and treatment of FGF23-mediated hypophosphatemic rickets.
Keywords
hypophosphatemic rickets
FGF23
phosphate metabolism
treatment options
X-linked hypophosphatemia
calcitriol
burosumab
autosomal dominant hypophosphatemic rickets
research
EndoCareers
|
Contact Us
|
Privacy Policy
|
Terms of Use
CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036
202.971.3636 | 888.363.6274
×